Skip to main content
TipRanks
Go Ultimate75% OFF

BTL, Inc. (6840) AI Stock Analysis

TW:6840

BTL, Inc.

(TPEx:6840)

Select Model
Rating:60Neutral
Price Target:TWD 64.00â–¼(-5.88% Downside)
Action:initiatedcoverage
Date:11/10/26

The score is supported primarily by earnings recovery and a stable balance sheet, but constrained by inconsistent free cash flow, weak technical momentum, and a relatively demanding P/E valuation. Earnings-call and corporate-event factors were excluded because no relevant data was provided.

Positive Factors
Revenue RecoveryThe rebound in revenue over two consecutive years indicates improving demand and execution after the 2023 decline. Continued top-line recovery can expand operating leverage, support reinvestment, and provide a stronger foundation for rebuilding the company’s longer-term earnings capacity.
Negative Factors
Negative Free Cash FlowRepeated negative free cash flow shows that improving accounting earnings are not yet consistently translating into discretionary cash. Capital spending or working-capital needs are consuming funds, which can limit financial flexibility and constrain the company’s ability to self-fund growth.

BTL, Inc. (6840) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%100%TW:6840+21.16%SPY+14.30%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 2.04B
Dividend Yield
1.47%
Average Volume (3M)
433.25K
Price to Earnings (P/E)
40.5
Beta (1Y)
1.25
Revenue Growth
13.53%
EPS Growth
65.33%
Country
TW
Employees
122
Sector
General
Sector Strength
55
Industry
Specialty Business Services

BTL, Inc. Business Overview & Revenue Model

Company Description

BTL, Inc. provides testing and certification services for electronic products. Its products include mobile communications, BQB, Sar/Ota, IoT, EMC, RF, telecom, safety and new energy. It offers certifications for electromagnetic compatibility (EMC), r...

BTL, Inc. Financial Statement Overview

Summary

Earnings recovered, with 8.5% revenue growth and improved net and EBIT margins, while the balance sheet remained stable with moderate leverage. However, profitability remains below historical peaks and negative, volatile free cash flow limits financial quality.

Income Statement

72Positive

Balance Sheet

74Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue961.85M909.14M838.24M702.81M888.20M825.06M
Gross Profit383.43M374.46M315.50M230.01M438.97M437.85M
EBITDA233.23M204.16M165.76M66.87M272.72M246.07M
Net Income66.05M47.96M15.50M-53.45M134.92M129.16M
Balance Sheet
Total Assets1.84B1.76B1.68B1.51B1.38B1.28B
Cash, Cash Equivalents and Short-Term Investments207.04M260.02M371.80M234.01M241.26M357.94M
Total Debt587.82M571.20M543.34M553.62M463.45M434.07M
Total Liabilities764.41M710.67M669.99M704.59M627.26M603.67M
Stockholders Equity1.08B1.05B1.01B808.61M753.41M673.23M
Cash Flow
Free Cash Flow-10.89M-26.23M13.12M-127.83M-74.47M157.15M
Operating Cash Flow179.04M170.53M94.49M33.19M170.44M224.79M
Investing Cash Flow-147.75M-114.25M-118.19M-135.04M-150.85M-128.36M
Financing Cash Flow-35.95M-86.04M138.05M127.91M-59.67M-35.37M

BTL, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:6840 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:6527TW:652773OutperformTWD 1.86B12.15―3.98%-1.23%10.20%
TW:4116TW:411662NeutralTWD 1.82B2.38―4.91%3.85%786.65%
TW:6840TW:684060NeutralTWD 2.09B40.48―1.47%13.53%65.33%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:6558TW:655847NeutralTWD 1.81B-10.57―1.55%-10.07%-349.71%
TW:6796TW:679640UnderperformTWD 2.04B123.00―0.51%12.26%―

* General Sector Average

Performance Comparison

-50%0%50%TW:6840TW:4116TW:6527TW:6558TW:6796TW:7881Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:6840 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:6840BTL, Inc.68.0010.8919.07%
TW:4116BenQ Medical Technology Corp.40.70-2.63-6.06%
TW:6527Crystalvue Medical Co Ltd72.90-5.53-7.05%
TW:6558SYNergy ScienTech Corp.19.45-18.05-48.13%
TW:6796Medimaging Integrated Solution Inc.49.20-39.14-44.31%
TW:7881Eyecare Tech, Inc.73.20-35.89-32.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026